Our Services
Medical Information
Helpful Resources
Published on: 2/28/2026
Liraglutide can underperform if you have not been on the full dose long enough, if biology and insulin resistance blunt its effects, if calorie intake or low activity offset benefits, or if hormones or true non-response are in play. There are several factors to consider; see below for realistic timelines, expected results, and urgent red flags like severe abdominal pain.
See below for next steps including tuning diet and strength training, checking labs such as TSH, A1C, fasting insulin, lipids, and liver enzymes, considering a switch to semaglutide or tirzepatide or adding combination therapy, and when surgery fits; do not stop the medication without talking to your doctor.
If you're taking liraglutide and not seeing the results you expected, you're not alone. While liraglutide is an FDA-approved medication for weight management and type 2 diabetes, not everyone responds the same way. Some people lose significant weight. Others lose very little. A small group may feel like it's "not working" at all.
The good news? There are usually clear reasons — and practical next steps.
Let's break down why liraglutide may not be working and what you can do about it.
Liraglutide is a GLP-1 receptor agonist. It mimics a natural hormone called glucagon-like peptide-1 (GLP-1), which:
For weight management, clinical studies show average weight loss of about 5–10% of body weight over 6–12 months when combined with lifestyle changes. But averages don't tell the whole story.
There are several possible reasons your body may not be responding as expected.
Liraglutide is started at a low dose and gradually increased to reduce side effects. It can take several weeks to reach the therapeutic dose.
If you're early in treatment, patience may be part of the process.
Obesity is not just about willpower. It involves:
Some individuals have stronger biological "defenses" against weight loss. The body may increase hunger hormones or reduce metabolic rate in response to calorie reduction — even when using liraglutide.
This doesn't mean failure. It means your biology is powerful.
Liraglutide improves insulin sensitivity, but in people with significant insulin resistance or long-standing type 2 diabetes, weight loss may be slower.
Signs of severe insulin resistance include:
In these cases, additional medications or metabolic interventions may be needed.
Liraglutide reduces appetite, but it doesn't eliminate it.
Some people:
Even small calorie surpluses can stall weight loss.
A short-term food log — even for 3–5 days — can provide clarity without becoming obsessive.
Exercise isn't required for weight loss, but it improves results and helps preserve muscle.
Without resistance or strength training:
Even modest activity — 2–3 days per week of strength work and daily walking — can enhance liraglutide's effect.
Certain medical conditions can blunt weight loss response:
If weight is completely unchanged after several months, screening labs may be appropriate.
In clinical trials, about 10–20% of people lose less than 5% of body weight on liraglutide.
Medicine isn't one-size-fits-all.
Some bodies respond better to:
It's not a personal failure if this medication isn't your match.
If you expected dramatic weight loss quickly, the process can feel disappointing.
Healthy, sustainable weight loss often looks like:
Non-scale victories matter:
Liraglutide may not be appropriate or effective if:
These situations require medical evaluation.
If you experience severe abdominal pain, persistent vomiting, chest pain, or symptoms that feel life-threatening, seek urgent medical care and speak to a doctor immediately.
If you've given liraglutide a fair trial (usually 3–6 months at full dose), here are evidence-based next steps.
With your clinician, review:
Small adjustments can significantly improve response.
Consider screening for:
Metabolic roadblocks can often be identified and addressed.
Other GLP-1–based medications may be more effective:
Some patients who don't respond to liraglutide respond well to another medication in the same family.
In certain cases, clinicians may add:
Combination therapy targets multiple appetite and metabolic pathways.
For individuals with severe obesity (BMI ≥40 or ≥35 with complications), metabolic surgery remains the most effective long-term treatment.
This is not a first step — but it is an evidence-based option for some people.
Do not stop liraglutide without speaking to your doctor.
Stopping abruptly may:
Any medication changes should be supervised by a healthcare professional.
If you're struggling with liraglutide or unsure whether your symptoms align with obesity as a medical condition, taking a free AI-powered assessment can help you identify contributing factors and prepare informed questions before your next doctor's appointment.
If liraglutide isn't working, it does not mean:
It means your biology may require a different strategy.
Obesity is a chronic, medical condition influenced by hormones, metabolism, genetics, and environment. One medication may help — but sometimes it takes adjustment, combination therapy, or a different approach altogether.
The most important next step is to speak to a doctor. Bring your concerns, your timeline, and your questions. Ask:
If you experience severe side effects, sudden abdominal pain, or symptoms that feel serious or life-threatening, seek immediate medical attention.
You deserve a treatment plan that works with your body — not against it.
(References)
* Nyström T, Nordin M. Mechanisms of Resistance to GLP-1 Receptor Agonists. Int J Mol Sci. 2023 Apr 28;24(9):8015. doi: 10.3390/ijms24098015. PMID: 37175402; PMCID: PMC10156947.
* Nauck MA. Response to GLP-1 receptor agonists: current status and challenges. Diabetologia. 2020 May;63(5):849-854. doi: 10.1007/s00125-020-05111-9. Epub 2020 Mar 5. PMID: 32139886; PMCID: PMC7167664.
* Gorgojo-Martínez JJ, Sanz-Rebollo M, González-Clemente JM. Strategies for the treatment of patients with type 2 diabetes not achieving glycemic control on GLP-1 receptor agonists. Endocrinol Diabetes Nutr (Engl Ed). 2021 Mar;68(3):184-192. English, Spanish. doi: 10.1016/j.endinu.2020.06.012. Epub 2020 Sep 28. PMID: 32994119.
* Calvillo-Ortiz H, Ramírez-Rodríguez S, Villarreal-Pérez JZ. Secondary failure to GLP-1 receptor agonists in type 2 diabetes: a narrative review. Endocrine. 2023 May;80(2):237-243. doi: 10.1007/s12020-023-03310-7. Epub 2023 Feb 1. PMID: 36725832.
* Sposito AC, Canales-Basurto N, Rossetti C, Jabbour SA, Fonseca VA, Lima T, Curiati C, Lopes MS, Solano S, Berti L, Siqueira A, Almeida C, Moreira AS, Fonseca J. Predictors of weight loss response to liraglutide in patients with obesity or overweight: a systematic review and meta-analysis. Obes Rev. 2020 Jun;21(6):e12992. doi: 10.1111/obr.12992. Epub 2020 Mar 2. PMID: 32115797.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.